Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2003
11/13/2003WO2003010281A3 Protein kinase inhibitors comprising atp mimetics conjugated to peptides or peptidomimetics
11/13/2003WO2003000889A3 Identification of ses-1 and the uses of the same
11/13/2003WO2002099115A3 Nucleic acid-associated proteins
11/13/2003WO2002098849A3 Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer’s disease and similar diseases
11/13/2003WO2002096879A9 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
11/13/2003WO2002088137A9 Pkb-3564 substance with neovascularization inhibitory activity
11/13/2003WO2002066681A3 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors
11/13/2003WO2002064796A8 Butyrylcholinesterase polypeptide variants with increased catalytic efficiency and methods of use
11/13/2003WO2002061033A3 Transfection of human embryonic stem cells
11/13/2003WO2002057226A8 68730 and 69112 protein kinase molecules and uses therefor
11/13/2003WO2002053139A8 Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
11/13/2003WO2002002520A8 Compounds to treat alzheimer's disease
11/13/2003WO2000021978A3 Laminin 5, 13 and 14 and uses thereof
11/13/2003US20030212273 Pyrrolo [2,3-D] pyrimidine compounds
11/13/2003US20030212145 Parkinson's disease; cognition activators; central nervous system disorders
11/13/2003US20030212143 Analgesics, anesthetics; crystallization, resolution
11/13/2003US20030212142 Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder
11/13/2003US20030212141 Serotonin antagonists
11/13/2003US20030212140 Analgesics; central nervous system disorders
11/13/2003US20030212138 Synergistic mixture; analgesics, antiinflammatory agents, cardiovascular disorders, anticancer agents
11/13/2003US20030212133 Muscle relaxation; brain disorders; antiepileptic agents
11/13/2003US20030212128 Crystalline particles of escitalopram oxalate having a median particle size of >40 mu m; cystallization by gradually cooling the solution of dissolved escitalopram oxalate at a controlled cooling rate; adding crystals of escitalopram oxalate and holding; isolating particles
11/13/2003US20030212114 Stable emulsion compositions
11/13/2003US20030212096 Analgesics, antiinflammatory agents, autoimmune disease, viricides, bactericides, antitumor agents, organ grafting, central nervous system disorders
11/13/2003US20030212094 Novel cyclic amide derivatives
11/13/2003US20030212091 Aryl ether substituted imidazoquinolines
11/13/2003US20030212082 Controlling neovascularization; angiogenesis inhibitors; therapy for strokes, cardiovascular disorders; antitumor agents; antidiabetic agents; antiarthritic agents; psoriasis
11/13/2003US20030212080 Adenosine A2a receptor antagonists
11/13/2003US20030212079 Antiischemic agents; central nervous system disorders
11/13/2003US20030212073 Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
11/13/2003US20030212070 Dietetics; cardiovascular disorders; hypotensive agents; psychological disorders
11/13/2003US20030212068 Antiinflammatory agents; antiallergens; antiarthritic agents
11/13/2003US20030212066 1-Sulfonyl pyrrolidine derivatives
11/13/2003US20030212065 Using a imidazolo(4,5,1-ij)quinoline compound
11/13/2003US20030212064 Triazolotriazinones and the use thereof
11/13/2003US20030212062 Morpholinone and morpholine derivatives and uses thereof
11/13/2003US20030212059 Adenosine A2a receptor antagonists
11/13/2003US20030212057 Substituted piperidines, medicaments containing these compounds, and methods for the production thereof
11/13/2003US20030212050 Administering cyclooxygenase inhibitor and acetylsalicylic acid
11/13/2003US20030212036 Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory heptitis
11/13/2003US20030212026 Induce immunology response
11/13/2003US20030212020 Antisense modulation of macrophage migration inhibitory factor expression
11/13/2003US20030212012 Prevention labor contraction; urogenital disorders
11/13/2003US20030211990 Central nervous system disorders; test kits
11/13/2003US20030211986 Protein a compositions and methods of use
11/13/2003US20030211984 Genetic engineering; antibodies; libraries
11/13/2003US20030211969 Administering activated protein c; controlling blood coagulation
11/13/2003US20030211608 Antisense modulation of glycogen synthase kinase 3 beta expression
11/13/2003US20030211559 Comprises composition for identifying therapeutic agents that inhibit proteolytic processing of amyloid precursor protein; treating nervous system disorders
11/13/2003US20030211542 Assays and methods of diagnosis and treatment based on use of sodium channels as targets for amyloid beta or its aggregates
11/13/2003US20030211529 Human Eag2
11/13/2003US20030211513 Intracellular signaling proteins
11/13/2003US20030211493 Comprises membrane protein for diagnosis, prevention and treatment of infections, cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory and metabolic disorders
11/13/2003US20030211178 Herbal composition for treatment of neuronal injuries and neuronal degeneration, methods to prepare the same and uses thereof
11/13/2003US20030211162 Heating with carrier; mixtur eof fine and coarse particle sizes
11/13/2003US20030211145 Antiinflammatory agents, analgesics, antiarthritic agents; liquid filled capsulaes
11/13/2003US20030211121 Therapeutic treatments for neuropsychiatric disorders
11/13/2003US20030211112 EGFR ligands and methods of use
11/13/2003US20030211106 Binding tumor necrosis factor to antibody
11/13/2003US20030211103 Use of primate IFN-gamma binding molecules
11/13/2003US20030211077 Stimulanting hematopoiesis
11/13/2003US20030211040 Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain
11/13/2003CA2787384A1 Polymeric adhesive transdermal patch comprising rotigotine for treatment of restless leg syndrome
11/13/2003CA2753371A1 Heterocyclic derivatives as opioid receptor modulators
11/13/2003CA2749172A1 Re-epithelializing pharmaceutical compositions comprising xanthan gum
11/13/2003CA2703698A1 Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
11/13/2003CA2487693A1 Method for producing preparations rich in tocotrienol
11/13/2003CA2485216A1 Therapeutic use of pacap, maxadilan, pacap receptor agonist and/or adcyap1r1 in the treatment of cns disorders
11/13/2003CA2485115A1 The treatment of pain with ifenprodil
11/13/2003CA2485098A1 Use of heat shock proteins to enhance efficacy of antibody therapeutics
11/13/2003CA2485093A1 Substituted imidazole derivatives: gabaa receptor ligands
11/13/2003CA2485065A1 Semicarbazide derivatives for combating thromboembolic diseases
11/13/2003CA2484959A1 Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
11/13/2003CA2484874A1 Monocompartment osmotic controlled drug delivery system
11/13/2003CA2484797A1 Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
11/13/2003CA2484600A1 Therapeutic use of selective pde10 inhibitors
11/13/2003CA2484599A1 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
11/13/2003CA2484597A1 Thiazolidinones and the use thereof as polo-like kinase inhibitors
11/13/2003CA2484582A1 Bombesin antagonists
11/13/2003CA2484551A1 Smart pro-drugs of serine protease inhibitors
11/13/2003CA2484396A1 Method for control of depression using c terminal growth hormone (gh) fragment
11/13/2003CA2484312A1 Catechin multimers as therapeutic drug delivery agents
11/13/2003CA2484189A1 Methionine aminopeptidase-2 inhibitors and methods of use thereof
11/13/2003CA2484173A1 4-azasteroid derivatives as androgen receptor modulators
11/13/2003CA2484162A1 Imidazo-triazine derivatives as ligands for gaba receptors
11/13/2003CA2484065A1 Inhibitors of histone deacetylase
11/13/2003CA2483904A1 Use of (3-(2-ethylphenyl)-5-methoxyphenyl)-1h-[1,2,4]-triazole for the treatment of autoimmune diseases
11/13/2003CA2483857A1 Use of dimesna for mitigating taxane induced neurotoxicity
11/13/2003CA2483846A1 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
11/13/2003CA2483806A1 N-acyl piperidine derivatives for use as melanocortin receptor ligands in the treatment of feeding disorders
11/13/2003CA2483787A1 Melanocortin receptor ligands
11/13/2003CA2483785A1 Combination of cyclooxygenase-2 inhibitors and thalidomide for the treatment of neoplasia
11/13/2003CA2483655A1 Methods and dosage forms for controlled delivery of oxycodone
11/13/2003CA2483573A1 Sulfonylquinoxalone acetamide derivatives and related compounds as bradykinin antagonists
11/13/2003CA2483120A1 Polymeric adhesive transdermal patch comprising rotigotine for treatment of restless leg syndrome
11/13/2003CA2483050A1 Optimization of transgene expression in mammalian cells
11/13/2003CA2482524A1 Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders
11/13/2003CA2477985A1 Time-resolved fluorescence assay for the detection of multimeric forms of a-.beta. or other aggregating polypeptides
11/12/2003EP1361277A1 Optimization of transgene expression in mammalian cells
11/12/2003EP1361229A2 Use of Tyrosine Kinase (PYK2) to produce antibodies
1 ... 1149 1150 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 ... 1833